![]() TACOMA, TACOMA SR, TACOMA SR-5, TOYOTA RACING DEVELOPMENT (TRD), TACOMA LIMITED, TUNDRA, TUNDRA SR, TUNDRA SR-5, TUNDRA TRD PRO, TUNDRA LIMITED, 4RUNNER, 4RUNNER SR-5, 4RUNNER LIMITED, 4RUNNER NIGHTSHADE, AND 4RUNNER TRD OFFROAD ARE REGISTERED TRADEMARKS OF TOYOTA MOTOR CORPORATION. Ripple has a full product pipeline in development.CHRYSLER, JEEP, JEEP WRANGLER, WRANGLER UNLIMITED, RUBICON, WRANGLER JK, WRANGLER TJ, WRANGLER YJ, CJ7, CHEROKEE, GRAND CHEROKEE, LAREDO, SRT, SRT8, TRACKHAWK AND TRAILHAWK ARE REGISTERED TRADEMARKS OF CHRYSLER GROUP LLC. Ripple's novel therapeutics provide for better outcomes for patients, easier management of care for physicians and lower costs for payors. The core feature of Ripple's Epidel™ technology is the ability to engineer sustained-release pharmaceuticals with surface erosion release kinetics without the use of polymers or excipients. Ripple Therapeutics Corporation is a clinical stage, privately held company that is focused on ophthalmic therapeutics with controllable, sustainable drug delivery. Hovione was the first Chemical/ Pharmaceutical Company to become a Certified B Corp, is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards. Hovione's culture is based on innovation, quality and dependability. In the inhalation area, Hovione offers a complete range of services, from API, formulation development and devices. Hovione provides pharmaceutical customers services for the development and compliant manufacture of innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. The company has four FDA inspected sites in the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. As a Contract Development and Manufacturing Organization (CDMO) with a fully integrated offering of services for drug substances, drug product intermediates and drug products. Hovione is an international company with over 60 years of experience in pharmaceutical development and manufacturing operations. " Our shared goal is to accelerate and broaden the access to this highly innovative and enabling technology for the benefit of our pharmaceutical customers and their patients worldwide." "We are thrilled to partner with Ripple, who developed a state-of-the-art platform for sustained release," says Dr. "Hovione's expertise in controlled, sustained drug delivery, along with their experience in chemical synthesis and pharmaceutical manufacturing, makes for a great partnership." Wendy Naimark, Ripple co-founder and Chief Technology Officer. "The combination of technology synergy, innovative vision and cultural fit makes collaborating with Hovione an exciting next step in the advancement of the Epidel® platform beyond the ophthalmic field," stated Dr. By incorporating Ripple's Epidel® platform into its toolbox, Hovione can expand its portfolio of novel drug delivery solutions to the pharmaceutical industry. Surface erosion-based drug release provides a highly effective way to control dose and duration. This enables higher drug loading, smaller size implants, defined and predictable biocompatible degradation products with straightforward and scalable manufacturing processes. The core feature of Ripple's Epidel® technology is the ability to deliver sustained-release pharmaceuticals with surface erosion release kinetics without the use of polymers or excipients. LISBON, Portugal, Ma/PRNewswire/ - Hovione, the specialist integrated CDMO, leader in spray drying and particle engineering, and Ripple Therapeutics, a leading ophthalmic sustained drug delivery company, have entered a strategic partnership to expand the use of Ripple's Epidel® platform beyond ophthalmic applications. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |